

Index

- 2-arachidonoylglycerol (2-AG), 12–13, 69, 131, 190, 300, 335
- 5-HT, 120
- 5-HT1A, 109
- 5-HTTLPR genotype, 123
- aberrant salience, 141, 145, 195
- Abnormal Involuntary Movement Scale (AIMS), 231
- Abnormal Motor Behaviour, 200, 201
- Acquired Immunodeficiency Syndrome (AIDS), 339
- acute administration of THC, 80, 159
- acute effects of cannabinoids, 231, 236
- acute effects of cannabis, 79, 225, 229, 235, 288, 302, 350
- on adolescents, 302
- on BD, 133
- on cognition, 76
- on cognitive performance, 82
- on mood and psychotic symptoms, 230
- on people with schizophrenia, 228
- on sleep, 336
- on working memory, 78
- acute effects of delta-9-THC, 233–234
- acute intoxication, 21, 24–25, 76–77, 156, 352
- addiction, 63, 285, 299–306, 331, 346
- cannabis, 246, 299, 301, 305
- definition, 299
- symptoms of, 303
- Addiction Severity Index (ASI), 246
- addictive potential of cannabis, 321, 346
- adipose tissue, 7
- adolescence, 31, 61–63, 68–69, 120, 134, 144, 280, 321, 327–328
- brain development, 302
- cannabis use in, 121, 123–124, 131, 148
- cannabis use in, 132
- exposure to cannabis in, 71, 351
- victimization in, 282
- withdrawal in, 290, 338
- adolescent
- brain, 69, *see also* brain
- cannabinoid exposure, 62–63, 65, 120
- THC exposure, 62–64
- AEA, 14–16, 63, 189–193
- age at
- exposure opportunity, 322
- first onset, 148
- first use, 148, 219, 234, 288
- initiation, 219
- onset of cannabis use, 160, 337
- onset of psychosis, 170, 235, 242, 351
- onset of psychotic disorder, 226
- agoraphobia, 107
- alcohol, 51, 53, 56, 116, 124, 129, 142, 281
- acute consumption, 124
- acute effects of, 228
- consumption, 323
- dependence, 195
- genetics of, 324
- intoxication, 121
- treatment of dependence, 54
- alcohol and
- amphetamine, 52–53
- cannabis, 55, 132, 247
- tobacco, 53, 55–56, 144, 274, 305
- alcohol use disorder, 133, 248, 304, 323–325
- allele, 123, 150, 219
- risk, 218–220
- valine, 150
- allosteric modulation, 2, 304
- alogia, 200, 241
- AM251, 335–336
- AM281, 335–336
- American Academy of Sleep Medicine (AASM), 333
- amphetamine, 53, 56
- anandamide, 120, 131, 178, 184, 189–190, 235, 292, 300, 302, 335, 341
- anandamide (AEA), 3, 12–13, 95, 190, *see also* AEA
- Andreasson, Sven, 149
- anhedonia, 52, 120, 140, 142
- animal models, 61–62, 72, 109, 171, 200, 203, 270–271, 288, 325
- cannabinoid exposure, 172
- cannabis use in, 72
- effects of CBD, 201–202, 204–205
- preclinical, 71, 212
- antipsychotic drugs, 185, 200, 247–248
- clozapine, 190, 201, 203, 247–248
- haloperidol, 24, 201, 203, 207
- olanzapine, 190, 246
- quetiapine, 24, 190, 253, 339
- risperidone, 24, 190, 340
- ziprasidone, 246–247
- antipsychotic medication, 158, 185, 207, 210–211, 233, 235, 243, 256, 340
- side effects of, 228, 242
- antipsychotic properties of CBD, 212
- antipsychotic treatment, 24, 54, 91, 95, 185, 195, 243, 351
- anxiety, 62–63, 110–111
- attacks, 108
- levels, 108–109
- anxiety and CBD, 109
- anxiety and depression, 111, 123, 246, 270, 287, 315
- anxiety and mood disorder (AMD), 108, 114, 334
- anxiety as a predictor of cannabis use, 115
- anxiety disorders, 107, 109, 111, 114–115, 134, 287, 289, 302, 315
- treatment, 107, 109, 116
- anxiety symptoms, 107, 109, 111, 114, 123, 134, 226, 315
- cannabis use, 108, 114, 116
- treatment, 116
- anxiogenic effects, 62, 109, 234
- anxiolytic
- drugs, 16
- effects, 62, 109–112, 235
- role of cannabis, 108, 111
- role of CBD, 110
- ascending reticular activating system (ARAS), 335
- attention, 71, 79, 81
- deficits in, 156, 159
- goal-directed, 79
- impaired, 79
- processing, 79
- sustained, 79
- verbal memory, 81
- Attention Deficit Hyperactivity Disorder (ADHD), 325, 328

Index

- attentional
 - bias, 80
 - control, 79–80
 - deficits, 272
 - processes, 80
 - salience, 80–81
 - set-shifting, 62, 271
- attenuated psychosis syndrome, 139
- attenuated psychotic symptoms (APS), 94, 142, 226–227
- avolition, 200, 241
- BD, 128–134
- biological gradient, 173
- biological plausibility, 52, 168, 171, 173
- biotypes, 91, 97–98
 - B1, 97, 99–100
 - B2, 97, 99–100
 - B3, 91, 97, 99–101
- bipolar disorder, 91, 94, 96, 128, 134, 140, 182, 184–185, 247, 315, 334, 341, 351, *see* BD
- bipolar-schizophrenia network on intermediate phenotypes (B-SNIP), 96, 105, *see also* B-SNIP
- blood-brain barrier, 7
- body mass index (BMI), 323, 329
- BPRS, 158, 207, 234
- Bradford Hill criteria, 168, 173
 - analogy, 167–168, 172–173
 - biological gradient, 168, 170–171, 173
 - biological plausibility, 168, 171, 173
 - coherence, 168, 172–173
 - consistency, 168–169, 173
 - experiment, 168, 171–173
 - specificity, 168, 172–173
 - strength, 168–169, 173
 - temporality, 168, 170, 173
- Bradford Hill, Sir Austin, 172
- brain, 1–2, 5, 52, 148, 179
 - adolescent, 61, 64, 99, 338
 - adult, 64, 120, 268
 - areas, 1, 13, 16, 94
 - dysfunction, 78, 80
 - function, 80, 157, 314, 350
 - impairments, 65, 77, 314
 - maturation, 69, 82
 - mesolimbic regions of the, 68
 - morphology, 70, 81, 132, 313
 - neurodevelopment, 25
 - physiology, 17
 - regions, 1, 7, 14, 91, 131, 183, 195, 212, 300
 - tissue, 17, 178, 189, 268, 323
- brain alterations
 - dependence-related, 82
 - functional, 69, 71
 - structural, 69, 71
- brain development, 95, 321, 329
 - adolescent, 72
 - critical periods of, 160, 302
- brainstem, 1, 179–180, 335
- Brief Psychiatric Rating Scale, *see* BPRS
- B-SNIP, 91, 96–97, 99, 101
- B-SNIP-1, 97–98
- Cambridge Study in Delinquent Development (CSDD), 123
- cancer, 110, 167, 352–353
- cannabichromene (CBC), 4
- cannabidiol, 4, 12, 43–44, 76, 91, 100, 107, 133, 156, 171, 234–235, 273, 291, 300, 346, *see also* CBD
- cannabigerol (CBG), 4
- cannabigerolic acid (CBGA), 5
- cannabinoid CB1 receptor, 178, 287, *see also* CB1 receptor
- cannabinoid CB2 receptor, 178, 180, *see also* CB2 receptors
- cannabinoid type-1 receptors, 91
- cannabinoids and sleep, 333
- cannabinol (CBN), 4
- cannabis
 - extracts, 6, 43, 46, 48, 205–206, 336
 - infused edibles, 46
 - intoxication, 76, 78–79, 141, 156, 226, 282
 - legalisation, 47, 55, 305
 - policy, 46, 48, 54–56
 - potency, 43–44, 47, 83, 171
 - resin, 43, 45, 48, 149, 171
- cannabis addiction, 302–303, 305
 - pharmacological treatments, 303
 - risk factors for, 301
 - schizophrenia, 261
 - treatment for, 299–300, 306
 - vulnerability to, 301–302
- Cannabis Experience Questionnaire (CEQ), 145, 225
- Cannabis sativa*, 12, 111, 346
- cannabis use, 51–56, 68–71, 76–83, 91–94
 - adolescent, 38, 54, 68–71, 97, 99, 101, 123, 132, 150, 218
 - adult, 31, 35–37, 55, 287
 - cognition, 76, 82, 156
 - pros and cons, 39
 - psychosis, 51–52, 246
 - recreational, 7, 51, 76, 121, 246, 261
 - risk, 32, 54, 56
 - synthetic, 24
- cannabis use and violence, 279–280, 282–283, *see also* violence
- cannabis use disorder, 24, 31, 68, 99, 115, 151, 257, 285–286, 299, 321, 339, *see also* CUD
- comorbid, 243, 287
- depression, 121
- development, 285
- genetic risk, 340
- heritable, 289, 321
- interventions, 161
- medications, 311
- psychotic disorder, 48, 169, 227
- schizophrenia, 145, 148–149, 173–174, 219, 221, 351
- sleep disturbance, 341
- symptoms, 43
- treatments, 317
- Cannabis Use Disorders Identification Test (CUDIT), 246
- cannabis withdrawal symptoms, 282, 285–292
 - genetic influences, 289
 - in adolescents, 288
 - nervousness, 285, 286, 289
 - race and ethnicity, 288
 - reversal of, 246
 - sex differences in, 288
 - sleep disturbance, 286
 - women, 288
- cannabis withdrawal syndrome, 161, 285, 287, 292, 300, 312, 340
 - treatment, 290–292
- cannabis-associated psychosis, 91–93, 99, *see also* CAP
- CAP, 91–93, 100–101
- Carlsson, Arvid, 189, 195–196
- catechol-methyl-transferase (COMT), 150, 233
- categories of violence, 280, *see also* violence
 - collective violence, 280
 - interpersonal violence, 280
 - self-directed violence, 280
- causality, 128–129, 216, 218, 242, 269
 - assessing, 167–168, 242, 326
 - criteria, 167–168
 - genetic, 221
 - genetic predisposition and, 220
 - question of, 143–144
 - reverse, 152, 170, 326, 351
 - temporality in, 170
 - test for, 272
- CB1 receptor, 7–9, 63–64, 81–82, 178, 180, 185, 190
 - activation, 2–3, 16
 - distribution through brain, 1–2, 179
 - hippocampus, 94
 - stimulation of, 4
 - THC effect, 171
- CB1 receptor agonists, 77, 79–80, 288

- CB1Rs, 268, 272, 300
CB2 receptors, 2, 9, 16–17, 21–22, 110, 180, 346
CBD, 5, 7–9, 83, 108–114, 149, 200–212, 346, 351–353
 effect of, 9, 81
 oral, 78
CBT, 258, 290, 303
CBT+CM, 290
CBT+MI, 256
CBT-I, 339–341
central nervous system, 12, 23, 178, 268, 333, 349, 353, *see also* CNS
cerebrospinal fluid, *see* CSF
CET, 254, 258
childhood, 61, 68, 151, 267, 272–273, 352
 abuse, 51, 100–101
 adversity, 152, 172
 depression, 121
 epilepsy, 346
 maltreatment, 93, 290
 trauma, 92, 99, 143, 242, 274, 351
cholecystokinin (CCK), 1, 180
cholinergic receptor nicotinic alpha 2 subunit, *see* CHRNA2
cholinergic systems, 311, 335
CHR, 142, 211–212, 226, 230, 235
Christchurch Health and Development Study (CHDS), 142
CHRNA2, 323–324
circadian
 disturbances, 335
 rhythm disorders, 334
 rhythmicity, 17
 rhythms, 335
Claridge, Gordon, 140
clinical assessment, 246
clinical high risk (CHR), 139, 169, 172, 211, *see also* CHR
clinical modifications (CM), 32
clinical trials, 109, 211–212, 248, 253, 292
 cannabinoids, 112
 CBD in, 101
 controlled, 207, 261
 investigating pharmacotherapies, 134
 need, 108
Clinician Administered Dissociative Symptoms Scale (CADSS), 158
clozapine, *see* antipsychotic drugs
CM, 257–258, 290, 303
CNS, 1, 12–13, 16, 178, 180, 184, 190, 192, 194
cognition
 effects of cannabis, 76–77, 81, 328
 impaired, 76, 81, 212
 cognitive behavioral therapy for insomnia, *see* CBT-I
 cognitive behavioural relapse prevention, 291
 cognitive behavioural therapy, 107, 290, 303, *see also* CBT
 cognitive enhancement therapy, *see* CET
 cognitive function, 1, 23, 61, 68, 76, 81, 212, 231, 282, 312–313, 352
 cognitive impairment, 24, 54, 64, 81, 97, 140, 200, 204, 206, 350
 acute, 350
 aspects of, 212
 assessment of, 204
 attenuated, 206
 domain-specific, 282
 persistent, 81
 resilience to, 76
 serious, 23
 transient, 62
 cognitive impairments of schizophrenia (CIAS), 157
 Community Assessment of Psychic Experiences (CAPE), 140, 150, 233
 comorbidity, 31, 329
 cannabis use and CUD, 326
 cannabis use and schizophrenia, 220–222
 chronological aspects, 129
 depression, 327
 mental health, 326
 psychiatric, 71, 111, 116, 287
 SAD-CUD, 116
 substance abuse, 279
 contingency management, 255, 257, 290, 303, *see also* CM
 cortical alterations, 70–71
 criminal penalties, 51, 55
 CSF, 95, 189–190, 192
 CUD, 76, 128, 247, 253, 257–261, 287–288, 290–291, 299, 305, 311, 315, 321–329
 dabbing, 46, 68
 delta-8-THC, 4, 9
 delta-9-tetrahydrocannabinol (THC), 1, 4, 12, 43, 76, 107, 120, 131, 140, 158, 171, 178, 196, 241, 268, 300, 336, 346
 delusional perception, 200
 depolarization-induced suppression of excitation (DSE), 3, 15
 depolarization-induced suppression of inhibition (DSI), 3
 depression, 120–125, 128, 172, 287, 325
 causes of, 120
 comorbid, 302, 327
 development of, 120
 levels of, 350
 long-term, 185, 196, 272
 long-term synaptic, 77, 268
 reduction in, 121
 unipolar, 184
 diacylglycerol lipase (DAGL), 3, 13, 192
 Diagnostic and Statistical Manuals, *see* DSM
 diminished emotional expression, 200
 discordant twin
 designs, 216
 model, 325
 study, 216, 218
 DLPFC, 182–185, 194
 CB1 receptor binding, 181, 183
 CB1 receptor density, 181
 dopamine, 13, 80, 82, 92, 150, 189, 195
 dopamine D2, 13
 dopamine transporter (DAT), 22
 dopaminergic
 agonist amphetamine, 201
 agonist apomorphine, 201
 function, 100
 hyperactivity, 272
 neurons, 272
 neurotransmission, 56, 81
 stimulant action, 22
 dorsolateral prefrontal cortex, 78, 132, 181, 184, 193, 258, *see also* DLPFC
 dronabinol, 25, 111, 158, 234, 291, 303–304, 339, 353
 drug policy, 299, 306
 DSM
 criteria, 96
 data, 96
 diagnoses, 91, 97
 disorders, 97
 DSM-5, 32, 286, 321, 334
 CUD, 35, 37
 diagnosis, 299
 symptoms, 285
 DSM-IV, 32, 226, 247, 285
 axis I disorders, 230
 criteria, 32, 143, 301
 CUD, 35, 37, 115
 diagnosis, 233, 289
 Dunedin cohort, 150
 Dunedin study, 148
 dysregulation, 100
 affective, 143, 145
 DAergic neurotransmission, 64
 endocannabinoid, 185, 338, 340
 epigenetic, 72
 gene expression, 72
 PPI, 172

Index

- early psychosis, 94, 161, 256–257, 261
 - eCB, 13
 - ligands, 12–14, 69
 - receptors, 69
 - regulation, 14–17
 - signaling, 12, 14–16, 69
 - system, 16, 69, 134, 270, 302, 304
 - ECS, 12, 15, 17, 95–97, 99–100, 178
 - effects of cannabis, 139, 152, 157,
 - 161–162, 178, 185, 225, 228, 241, 243–244, 273, 300, 305
 - antiemetic, 353
 - beneficial, 229
 - biological, 131
 - chronic, 101, 161, 226
 - cognitive, 225, 231, 233, 241, 246, 313
 - detrimental, 9, 120, 346
 - developmental, 72
 - enhanced, 311
 - euphoric, 311
 - harmful, 56
 - health, 44, 111
 - interactive, 315
 - long-term, 77, 80, 108, 226, 241, 338, 350
 - mood-enhancing, 230
 - negative, 229, 234
 - positive, 287
 - pro-psychotic, 235
 - psychopathological, 282
 - residual, 80
 - reversible, 240
 - rewarding, 311
 - subjective, 226
 - tolerance to, 299
 - withdrawal, 337, 341
- effects of cannabis on
 - bipolar disorder, 131, 133
 - brain, 125, 132, 151, 350, 352
 - cancer pain, 353
 - cognition, 76, 81–83, 327
 - psychosis, 174, 253, 256
 - psychosis expression, 145
 - psychosis proneness, 144
 - psychotic disorders, 132
 - social behavior, 120
 - verbal memory, 81
 - effects of CBD
 - on abnormal motor behaviour, 200, 206
 - on altered social behaviour, 201
 - on patients with psychosis, 208
 - on sensorimotor gating deficits, 203
 - on working memory, 204
 - electroencephalography (EEG), 157, 162, 333
 - electrooculography (EOG), 333
 - electrophysiology, 92, 101
 - endocannabinoid signalling, 196
 - endocannabinoid system, 9, 131, 157,
 - 171–172, 267–268, 328, 335–336, 338, 349, *see also* ECS
 - cannabis effects, 1, 107, 120, 148
 - cholinergic systems, 311
 - components, 63, 184
 - phytocannabinoids, 5
 - role of, 1, 64
 - schizophrenia, 190
 - sleep, 333, 335, 340–341
 - slow self-inhibition, 4
 - THC effects, 82, 114
- endocannabinoid tone, 64
 - endocannabinoids, *see* eCB
 - endocannabinoids and sleep, 335
 - endogenous cannabinoid system, *see* ECS
 - endophenotype, 92, 139, 203
 - measures, 92
 - neurobiological, 131
 - environmental
 - causal relationship, 173
 - effect, 322
 - effects, 174
 - exposures, 51, 123
 - factors, 68, 216–217, 220, 300, 321, 328
 - influences, 100
 - manipulations, 61
 - risk factors, 65, 93, 140, 143, 151, 167, 243, 327
 - epigenetics, 72
 - epilepsy, 9, 346, 353
 - euphoric effects of cannabis, 311, 316
 - European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), 25, 171, 279
 - event-related potentials (ERP), 157
 - excitotoxicity, 82, 94, 98
 - exocannabinoids, 336
 - exocannabinoids and sleep, 336
 - exogenous cannabinoid, 8, 16, 25, 63, 134, 185, 302, 338, 341
 - externalizing
 - behaviour, 270, 274
 - problems, 267, 269
 - psychopathology, 281, 325–326
 - symptoms, 270
 - syndromes, 321
 - eye movements, 92, 101, 333, 337
 - Eysenck, Hans Jürgen, 140
 - false memories, 78
 - false negatives, 274
 - false positives, 271, 273–274
 - familial confounding, 143, 173, 216–218, 274
 - familial predisposition, 150, 173
 - family history, 51, 217
 - of affective dysregulation, 143
 - of alcohol and drug dependence, 321
 - of psychiatric disorder, 51
 - of psychopathology, 274
 - of psychosis, 51, 150, 174
 - of psychotic disorders, 150, 160
 - of psychotic illnesses, 93
 - of schizophrenia, 92, 150, 218, 226
 - family psychopathology, 144
 - family studies, 173, 216–218, 321
 - fatty acid amide hydrolase (FAAH), 14, 131, 184, 192, 253, 290, 292, 300, 304, 335
 - FEP, 240–244
 - first episode psychosis, 91, 171, 225, 227, 229, 350–351, *see also* FEP
 - first-line pharmacological treatments, 107
 - frequency of amphetamine injection, 53
 - frequency of use, 31, 54, 70–71, 108, 171, 240, 283, 305
 - G protein-coupled receptors, 2, 12, 179, *see also* GPCRs
 - GABA, 16, 92, 95, 100, 180
 - interneurons, 186
 - synapses, 190, 196
 - GABA_A receptor agonist, 339
 - GABA_A receptors, 13
 - GABAergic
 - abnormalities, 93
 - activity, 98
 - neurons, 2–3
 - neurotransmission, 99
 - synapses, 15, 64
 - system, 64
 - transmission, 172
 - gabapentin, 253, 291, 304
 - gamma aminobutyric acid, *see* GABA
 - gateway hypothesis, 63, 325–326
 - Gene x Environment interplay, 148
 - generalized anxiety disorder (GAD), 107–108, 334
 - genetic causality proportion, 221
 - genetic confounding, 170, 173, 326–327
 - genetic correlation, 216
 - genetic influences on cannabis use, 321
 - genetic predisposition, 124, 131–132, 148, 167, 217, 220, 222
 - Genetic Risk and Outcome of Psychosis (GROUP), 143, 150
 - genetic risk score, 219
 - genetics, 5, 72, 123, 221, 289
 - behavioral, 216
 - cannabis use, 323
 - role of, 321

- genetics of
 - alcohol, nicotine and opioid use disorders, 324
 - comorbid SUD, 324
 - nicotine dependence, 324
- genome-wide
 - data, 218
 - genetic correlation, 220
 - genotyping, 218
- genome-wide association studies, *see* GWAS
- global assessment of functioning (GAF), 247
- glutamate, 53, 98, 100, 179–180, 186
 - adaptations, 190
 - hippocampal, 95, 101, 272
 - measures, 94
 - neurotransmission, 94
 - release, 16, 109
 - signaling, 94
 - synapses, 196
- glutamatergic
 - agents, 62
 - deficits, 203
 - markers, 64
 - model, 200, 203
 - neurons, 1, 3
 - pathways, 3
 - receptors, 272
 - signaling, 272
 - synapses, 15, 64
 - system, 204
 - transmission, 172
- GPCRs, 2–4, 13–14
- grey matter density (GMD), 69, 99, 132
- grey matter volumes (GMV), 131
- GWAS, 139, 150, 218–222, 301, 322, 324–325, 327, 340
- hallucinations, 156, 200, 207, 228–230
 - auditory, 226–227
 - visual, 227
- haloperidol, *see* antipsychotic drugs
- hashish, 45, 167, *see also* cannabis resin
- health education, 55
- hepatotoxicity, 23
- herbal cannabis, 43–47, 149, 156, 160, 171, 235
- heritability, 321–323
 - of cannabis use, 321–322
 - of CUD, 321
 - of schizophrenia, 149
 - of substance, 328
- high-potency cannabis, 148–149, 152, 171, 222, 234, 279, 300, 327
- hippocampus, 77, 91, 94–95, 98–99, 179–181, 184, 313
- histone methylation, 72
- HLS, 158–159
- human laboratory studies, 139, 157, 288, 291, *see also* HLS
- Huntington’s disease, 111, 184
- hyperlocomotion, 62, 201
- ICD-10-CM, 32
- ICD-9-CM, 32, 37
- IMAGEN consortium, 69, 71
- immunohistochemistry, 1, 180, 182–183
- Indian Hemp Drug Commission, 167
- inhibition, 2–3, 80, 180, 185, 301
- inhibitory control, 24, 71, 82, 270, 300
 - impaired, 80, 272
- in-situ radioligand binding, 180, 185
- Interactive Observation Scale for Psychiatric Inpatients (IOSPI), 207
- internalizing
 - disorders, 325
 - problems, 270
 - psychopathology, 325–326
 - psychopathology and cannabis, 281
 - symptoms, 267, 270
- International Classification of Diseases 11th Revision (ICD-11), 299
- International Classification of Diseases and Related Health Problems [ICD]-10 and ICD-11, 285
- intoxication, 23, 55
- intrauterine growth restriction (IUGR), 272
- JWH-018, 21–22, 24, 226
- latent causal variable (LCV), 221
- learning and memory, 17, 62, 77, 246
- legal high, 21
- legal markets, 46–47, 56
- legalisation, 46, 55–56, 83, 305
 - adult cannabis use, 55
 - alternative approaches to, 48
 - cannabis, 76
 - medical cannabis, 305
- lifetime cannabis use, 99, 124, 130, 141–143, 151, 157, 174, 220, 288, 321, 323–324, 326, 328
- linkage disequilibrium score regression (LDSR), 143, 220
- liver fibrosis, 352
- long-acting injectable antipsychotics (LAIs), 211, 243, 246, 351
- long-term course of psychosis, 240, 242–244
- long-term depression (LTD), 3, 15, 95
 - heterosynaptic, 4
 - homosynaptic, 4
- magnetic resonance imaging (MRI), 131, 300, *see also* MRI
- magnetic resonance spectroscopy, 93, 95
- major depression, 121, 182–183, 185, 194–195, 289, 323–324, 327
- major depressive disorder (MDD), 120, 130, 327, 334, *see also* depression
- MAM-2201, 22
- marijuana, 12, 21, 24, 32, 39, 44, 68, 315, 338
- maternal health practices and child development study, 268–269, *see also* MHPCD
- maternal immune activation (MIA), 200, 203
- maturation processes, 63–64, 302
- measured evoked response (ERPs), 145
- medical use of cannabis, 305, 353
- medicinal cannabis, 107–108, 111, 156, 336, 339, 346
- memory impairment, 43, 77, 148, 272
- Mendelian randomization (MR), 124, 220, 326, 346, 352
- Mendelian randomization studies, 143, 174, 326, 346
- mental health, 256, 332–333, 351, 353
 - conditions, 289
 - disorders, 107, 111, 289, 301
 - outcomes, 123, 315
 - problems, 279, 301
 - risks, 51, 54–56
 - services, 56, 257
- mental illness, 24, 32, 51, 54, 129, 157, 167, 189, 195–196, 257, 279
- mesocorticolimbic dopamine systems, 258
- mesolimbic dopamine, 311
- MET, 258, 292, 303–304
- meta-analytical evidence, 168
- metabotropic induced suppression of excitation (MSE), 3
- metabotropic induced suppression of inhibition (MSI), 3
- methamphetamine, 53
- methylation mechanism, 72
- methylazoxymethanol (MAM), 200, 203
- MHPCD, 268, 270–271, 273
- MI+CBT, 253, 256–257
- MI+TAU, 253
- mindfulness-based relapse prevention, 291
- mismatch negativity, *see* MMN
- mitogen-activated protein kinases (MAPKs), 2
- MK-801, 201, 203–206
- MMN, 157, 159, 162
- model of Claridge, 139–140

Index

- model of Eysenck, 140
- molecular genetic studies, 216, 218, 222, 288
- mood disorders, 63, 120, 125, 130, 134, 286, 327–328
- motivational enhancement therapy, 256, 290, 303, *see also* MET
- motivational interviewing (MI), 247, 253–254
- motor vehicle accidents (MVA), 346, 352
- MR, 221
 - analysis, 328
 - study, 220, 327, 346, 351
- MRI, 92, 97, 99, 101, 132, 350
- mRNA, 1, 180, 182–185, 194
- multiple sclerosis, 111, 346, 353
- myelinogenesis, 268

- nabilone, 25, 109–111, 158, 291–292, 304
- nabiximols, 25, 79, 111, 291
- n-acetylcysteine, 250, 291–292, 304
- National Academies of Sciences, Engineering, and Medicine (NASEM), 111
- National Epidemiologic Survey on Alcohol and Related Conditions (NESARC), 32, 115, 281, 315, *see also* NESARC
- National Institute on Alcohol Abuse and Alcoholism (NIAAA), 32
- National Survey on Drug Use and Health, *see* NSDUH
- natural progression of cannabis use, 305
- nausea and vomiting, 110, 339, 346, 353
- NCAM1, 323–324, 328–329
- neglect, 280
- NESARC, 36, 116, 130
- NESARC-III, 37
- Netherlands Mental Health Survey and Incidence Study (NEMESIS), 142–144
- neural activity, 97, 120, 159, 314
- Neural Cell Adhesion Molecule 1, *see* NCAM1
- neural development, 268
- neural integrative defect, 140
- neural progenitors, 268
- neuroadaptations, 300
- neurobiological mechanism, 61, 72, 131–132
- neurobiological model of tolerance, 81–82
- neurobiological systems, 311
- neurobiology, 128, 132–133, 236, 333, 335, 337
- neurocognitive
 - deficits, 157
 - dysfunction, 204
 - functioning, 128
 - impairment, 93, 132
 - performance, 92, 141, 211, 348
- neurodevelopment, 69–70, 80–83, 95, 123, 148, 267, 272, 321, 327–329, 333
- neurodevelopmental
 - abnormalities, 100
 - changes, 68
 - disorders, 25, 328
 - disruption, 151
 - maturational processes, 302
 - models, 203–204
 - period, 120
 - phenotype, 328
 - processes, 65
 - rat models, 206
 - trajectories, 82
 - vulnerability, 241
- neuroimaging, 109, 194, 274
 - assessments, 161
 - conditions, 70
 - evidence, 148
 - investigation, 133
 - research, 94
 - studies, 69, 71–72, 78, 131, 350
 - techniques, 350
- neuroinflammation, 9, 64
- neuromodulatory system, 1, 12, 21
- neuronal dynamics, 82
- neuropathy, 111
- neuropharmacology, 189
- neurophysiological abnormalities, 159, 235
- neurophysiology, 189, 195
- neuroprotective effects, 13, 161
- neurotoxicity, 22
- neurotransmitter release, 3–4, 7, 9, 12–13, 15, 180, 189
- nicotine, 310, 313, 324
 - dependence, 152, 221, 315, 324
 - effects of, 312–313
 - patch, 253, 311–312
 - withdrawal, 312
- NMDA, 201, 203, 206
- N-methyl-D-aspartate, 14, 82, 200, *see also* NMDA
- non-REM, *see* NREM
- norepinephrine (NE), 13, 53, 120
- novel etiological pathways, 107
- novel psychoactive substances (NPS), 21
- NREM, 333, 335–336
- NREM1, 333
- NREM2, 333
- NREM3, 333, 339
- NSDUH, 32–38

- observational data, 167
- offspring outcomes, 271
- olanzapine, *see* antipsychotic drugs
- OPPS, 269, 271
- Ottawa Prenatal Prospective Study, *see* OPPS
- outcome dimensions of psychosis, 241–242
- oxytocin, 252–253, 291

- pain control, 346, 352
- panic disorder (PD), 107–108, 130
- PANSS, 158, 190, 207–211, 231
- paranoid ideation, 156
- parental THC exposure, 272
- Parkinson Psychosis Questionnaire, 207
- Parkinson’s disease, 111, 113, 206, 235
- Parkinson’s Disease (PD), 207
- pattern, 289
 - age, 35
 - assessment of cannabis use, 246
 - banded, 182
 - banding, 183
 - between cannabis and psychosis, 156
 - cannabis and tobacco co-use, 315
 - dose-response, 351
 - frequent use, 287
 - in relation to violence, 280
 - levels of cannabis use, 301
 - mRNA expression, 183
 - substance use, 21
 - usage, 306
 - variation in, 43
- pattern of
 - altered CB1, 340
 - binding, 182–183
 - brain regional densities, 180
 - cannabis use, 24, 129, 152, 234, 240–241, 243–244, 288, 299, 306, 340
 - cannabis use during adolescence, 68
 - cognitive and psychophysiological deficits, 158
 - distribution, 180
 - hippocampal glutamate, 101
 - impairment to adults, 82
 - medical cannabis use, 107
 - results, 270, 314
 - substance use, 274
- PCE, 267–274
- perceived risk, 36–38, 68, 167
- perceptual alterations, 158, 200, 233
- PET, 194–195, 300
- PF-04457845, 253, 304, 339

- pharmacokinetics, 1, 5, 7, 305
THC, 7
- pharmacological dopaminergic models, 200
- pharmacological effects, 22, 24, 151
- pharmacological treatments, 107, 247, 249
- pharmacotherapy, 253, 291–292
- pharmaco-toxicological
actions, 23
responses, 22
- phenomenology, 96
- phosphatidylinositol-3-kinase (PI3K), 2
- physical health, 311
improve, 315
problems, 316
- physiological functions, 16–17
- phytocannabinoids, 2, 4–5, 9, 134, 158
- Pittsburgh Sleep Quality Index (PSQI), 114
- PMI, 181–182
- polygenic risk score (PRS), 52, 91, 97, 99, 101, 143, 151, 174, 227, 274, 327, 329
- polygenic risk score for schizophrenia, 139, 150, 160, *see also* PRS-SZ
- polygenic scores, 218–220, 270
- polyinosinic-polycytidylic acid, 203
- polysomnography, *see* PSG
- population attributable risk fraction (PARF), 169
- Positive and Negative Syndrome Scale, *see* PANSS
- positive symptoms, 52, 93, 95, 150, 190, 200, 211, 228, 241, 282
improve, 258
increased, 231
of psychosis, 139, 172, 204, 246
reduction in, 235, 256
relief of, 229
- positron emission tomography, *see* PET
- post-mortem
brain tissue, 190
component, 184
findings, 193
human brain data, 185
human brain studies, 180, 185
human brain tissue, 178, 180–181, 184
schizophrenic brain tissue, 195
studies, 190
- post-mortem interval, 178, 181, *see also* PMI
- potency, 2, 8, 273
- potency of delta-9-tetrahydrocannabinol, 68, 149, 161
- potential neurobehavioral mechanisms, 246
- PPI, 62, 172, 203–204, 206, 212
- prefrontal cortex, 1, 77, 132, 150, 171, 180, 182, 192
- prefrontal cortical (PFC), 68
- pregnancy, 203, 267–271, 273–275, 352
- premorbid IQ, 92, 151
- prenatal cannabis exposure, *see* PCE
- prenatal development, 268
- prenatal infection model, 200
- prepulse inhibition, *see* PPI
- processing speed, 80–81, 132
- prodromal psychotic symptoms, 151
- prodromal stage, 68
- prodromal states, 139
- Profile of Mood States (POMS), 111
- prognosis of psychosis, 244
- propensity score (PS), 123
- PRS-SZ, 143, 150–151
- PSG, 333–335, 339
- psychiatric disorder, 61, 91, 97, 124, 128, 150, 172, 287, 327, 329
- psychiatric illness, 68, 70, 226, 258, 334, 341
- psychoactive component, 1, 68, 110, 178, 273, 291, 324
- psychoactive effects, 8, 12, 21, 43, 69, 95, 234, 324
- psychoactive substances, 31, 33, 243
- psychoactivity of cannabis, 1, 5, 9
- psychopharmacological treatment, 116
- psychosis, 148
cannabis-induced, 131, 150, 156, 161
cause of, 51, 53, 189, 240
expression, 139, 142–145
family history of, 51, 55, 150, 174
first-episode, 131, 149, 151–152, 219, 226, 234, 256–257, 327
levels of, 143
onset of, 43, 101, 148, 151–152, 170, 235, 240, 242, 351
risk of, 145, 149, 158, 160, 170, 174, 246, 351
synthetic cannabinoid-induced, 24
- psychosis disorders, 351
- psychosis proneness, 139–142, 144, 151, 225, 267, 270
- psychosocial interventions, 133–134, 253
- psychostimulants, 22, 51, 299–300
- psychotic disorders, 25, 55–56, 91, 93, 97, 132, 139–140, 149, 225, 236, 246, 351
- psychotic illnesses, 91–93, 100
- psychotic symptoms, 24, 51, 172, 207, 211, 226, 229–230, 233
acute, 95
amphetamine use and, 56
- cannabis use on, 228
improved, 207
measured, 170
negative, 52, 233, 351
onset of, 156
positive, 171, 189–190, 244
pre-existing, 226
prognosis for, 335
risk of, 51, 130, 151
severity of, 53
subclinical, 139, 150
THC-induced, 95, 159, 172, 178, 234
transient, 80, 160
- psychoticism, 139–140
- Psychotomimetic States Inventory (PSI), 158
- psychotomimetic symptoms, 161, 235, 302
- psychotropic effects, 12, 17, 268
- quantitative autoradiography, 180–182, 185, 193
- quetiapine, *see* antipsychotic drugs
- randomised controlled trial, 133, 206–207, 220, 247, 290, 305, 346, *see also* RCT
- rapid cycling bipolar disorder, 129
- rapid eye movement, *see* REM
- RCT, 54, 111, 220, 291–292, 353
- recovery, 78–79, 93
CB1 receptor hypofunction, 82
cognitive, 82, 92
cognitive impairment, 81
driving-related cognitive skills, 350
memory function, 77
psychosis, 244
symptomatic, 114
verbal learning, 77
visuospatial, 77
working memory, 79
- recreational cannabis, 7, 9, 51, 76, 121, 149, 158, 246, 261, 305, 321
- relapse, 152, 290
cannabis, 311, 316
heroin, 63
prevention, 256, 259, 291
psychosis, 43, 243, 347
psychotic, 226
risk of, 76, 240–244, 282, 292
schizophrenia, 351
temporary, 95
- relapse prevention (RP), 257, 303
- relative risk (RR), 167, 173, 192, 273
- REM, 286, 333–341
- repetitive transcranial magnetic stimulation, *see* rTMS

Index

- residual effects, 81
 - on cognition, 76
 - on inhibitory control, 80
 - small-to-moderate, 79
 - subacute, 76, 79
 - working memory, 79
- retrograde signaling, 2, 9, 12
- rimonabant, 2, 8–9, 131, 182
- risk, 31–32, 54, 64, 68, 125, 169, 279
 - allele, 218–220
 - genetic, 92, 97, 99, 139, 143, 145, 228, 326, 340
 - health, 21, 315
 - medical, 346
 - psychiatric, 68, 72
- risk of
 - addiction, 300, 302
 - cannabis use, 55, 115, 145, 169, 221
 - CUD, 38, 68, 151, 305, 323
 - depression, 121, 123, 329
 - developing BD, 129–131
 - enhancing pharmaco-toxicological effects, 22
 - motor vehicle accident, 346, 352
 - neurodevelopmental disorders, 25
 - psychiatric disorder, 9
 - psychosis, 24, 48, 51–53, 139, 148, 150, 157, 160, 170, 225
 - psychotic disorder, 43, 230
 - relapse, 43, 76, 240–244, 282, 292, 351
 - schizophrenia, 93, 139, 143, 149–151, 160, 173, 216, 221
 - SUD, 130
 - suicidal behaviours, 124
 - violence, 281–282
- risperidone, *see* antipsychotic drugs
- route of administration, 1, 6, 68, 76–77, 81, 108, 158, 305, 336, 350
 - inhalation, 310
 - oral, 158–159
- rTMS, 258, 261
- safety profile, 200
- safety profile of cannabis, 76, 83
- schizophrenia, 178, 180–186, 189–191
 - causal effect of cannabis, 216, 220–221, 327
 - causal relationship between cannabis use, 220–221
 - genetic overlap between cannabis use and, 217, 220, 222
 - link between cannabis use and, 148, 216
 - polygenic score for, 219
 - relationship with cannabis, 216–217, 221
 - symptoms, 52
 - schizophrenia spectrum disorder, 156, 167, 200, 212, 225
 - schizophreniform psychosis, 148, 228
 - schizotaxia, 139–140
 - schizotypal disorder, 141
 - schizotypal personality organization, 140
 - Schizotypal Personality Questionnaire (SPQ), 140, 225
 - Schizotypal Trait Questionnaire (STQ), 140
 - schizotype, 139, 225
 - schizotypy, 139–141, 145, 161
 - high, 145, 225
 - negative, 140–141, 150
 - positive, 140, 150
 - selective serotonin reuptake inhibitors (SSRIs), 107
 - self-medication, 52, 114, 121, 123–125, 152, 225, 229, 242, 246
 - sensorimotor gating, 62, 172, 203, 212
 - serotonin, 195
 - serotonin 5-HT, 22, 120
 - serotonin 5HT1A receptor, 9
 - serotonin noradrenalin reuptake inhibitors (SNRIs), 107
 - sex differences, 72, 82, 124
 - sex-specific effects, 72
 - sexual abuse, 152
 - shared environmental factors, 216, 301
 - shared genetic factor, 52, 216, 218, 220–221
 - shared genetic predisposition, 216, 242
 - sibling pair study, 217
 - Simpson Angus Scale (SAS), 231
 - single nucleotide polymorphisms (SNPs), 143, 218, 290, 323, *see also* SNP
 - Single Photon-Emission Computed Tomography (SPECT), 109
 - skunk, 149, 234, 241
 - sleep disturbances, 334–335, 338–341
 - sleep efficiency, 335, 337, 339–341
 - sleep efficiency (SE), 334
 - sleep onset latency, *see* SOL
 - sleep/wake cycle, 335–336, 340
 - slow self-inhibition (SSI), 4
 - slow wave sleep, *see* SWS
 - SNP variants, 323
 - SNP-based genetic correlations, 220
 - SNP-H2, 323
 - social anxiety disorder (SAD), 107–108
 - social dysfunction, 200, 206
 - social interaction impairments, 203
 - socio-economic status (SES), 124, 173, 324
 - SOL, 335–338
 - spontaneously hypertensive rat (SHR), 200, 201, 203, 204
 - SPQ, 141
 - standard care (SC), 256
 - Start Over and Survive (SOS), 256
 - State-Trait Anxiety Inventory (STAI), 110
 - Strainprint Cannabis Tracker, 108
 - striatal dopamine, 172, 179
 - release, 144
 - striatal dopaminergic activity, 148, 246
 - networks, 246
 - Substance Abuse and Mental Health Services Administration, 32, 36–37
 - substance use, 247, 256
 - in adolescence, 272
 - persistent, 243
 - psychoactive, 243
 - treatment programs, 24
 - violence, 280–282
 - substance use disorders, 32, 69, 124, 133, 225, 256, 289–290, 299, 314, 324, *see also* SUD
 - SUD, 128–130, 133–134, 248, 258, 314–315, 324–326, 328
 - sudden infant death syndrome (SIDS), 53
 - suicidal ideation, 22, 24, 120–121, 124, 172, 327, 351
 - suicidality, 124, 327
 - suicide, 128, 181–182, 185
 - attempts, 121, 124, 128–129, 134, 334, 351
 - death by, 129, 183
 - non-schizophrenia, 182
 - SWS, 286, 334, 336–338, 340–341
 - synaptic plasticity, 3–4, 64, 72, 77, 82, 328
 - synaptic pruning, 64, 68
 - synaptogenesis, 267–268
 - synthetic cannabinoid
 - agonists, 21–25, 159
 - psychosis, 24, 156
 - schizophrenia, 226
 - treatment, 286
 - user, 24
 - synthetic cannabinoid AM-2201, 226
 - synthetic cannabis, 24–25
 - TAU, 253, 256–257
 - terpenes, 5
 - tetrahydrocannabinol (THC), 52, 285, *see also* delta-9-tetrahydrocannabinol (THC)
 - tetrahydrocannabivarin (THCV), 4, 82
 - tobacco, 167, 173, 311–316, 351
 - abstinence, 312
 - alcohol and, 53, 56, 123, 144, 324

cognitive function, 313	types of violence, 280–281, <i>see also</i>	violent crime, 279–280
control policies, 56	violence	vulnerability, 24, 61, 68, 92, 150, 287, 300
co-use, 310–311, 314–316	neglect, 280	adolescent, 302
depression, 123	physical violence, 280–281	age-dependent, 302
effects of, 243, 313	psychological violence, 280	behavioural, 71–72
exposure, 268, 310, 312	sexual violence, 280	cannabis addiction, 301
smoking and schizophrenia, 52, 323	UHR, 139, 141–142, 227	genetic, 63, 93, 227, 241, 325, 329
withdrawal, 286	ultra-high risk, <i>see</i> UHR	opioid, 63
total sleep time, <i>see</i> TST	umbrella review, 168, 172	psychiatric, 69
toxicity, 21–22	vanilloid (VR1), 178	psychosis, 24, 144, 148
TRacking Adolescents' Individual Lives Survey (TRAILS), 144	vaping cannabis, 68	wake time after sleep onset, <i>see</i> WASO
trans-theoretical model, 247	violence	WASO, 335–338, 340
treatment as usual, <i>see</i> TAU	among ethnic minorities, 281	wetware hypotheses, 189, 195–196
treatments, 62, 68, 97, 107, 114, 261	assessing, 280	WIN55,212-2, 120
behavioural, 290, 311, 316	cannabis and, 282–283	working memory, 71, 78–79, 81, 93, 95, 156, 200
cannabis, 353	categories of, 280	deficits, 145, 159, 162
FDA-approved, 338	definition, 280, 283	impairments, 196, 206
non-substitution, 304	interpersonal, 281	performance, 62, 78
pharmaceutical, 92	intimate partner, 281	processes, 62
pharmacological, 54, 107, 236, 303–304	perpetration in adolescence and early adulthood, 281	years of life lived with disability (YLDs), 200
psychopharmacological, 116	physical, 281	ziprasidone, <i>see</i> antipsychotic drugs
psychosocial, 303	psychological, 280	
sleep disturbances, 333, 340	risk of, 282	
TST, 335, 337–338, 340	sexual, 280	
twins, 192, 219, 322	types of, 280–281	
di-zygotic, 327	typology of, 280	
monozygotic, 216, 325, 327	victim of, 281–283	